Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer

TY - JOUR

T1 - Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer

AU - Lebok, Patrick

AU - von Hassel, Aurelia

AU - Meiners, Jan

AU - Hube-Magg, Claudia

AU - Simon, Ronald

AU - Höflmayer, Doris

AU - Hinsch, Andrea

AU - Dum, David

AU - Fraune, Christoph

AU - Göbel, Cosima

AU - Möller, Katharina

AU - Sauter, Guido

AU - Jacobsen, Frank

AU - Büscheck, Franziska

AU - Prien, Kristina

AU - Krech, Till

AU - Krech, Rainer Horst

AU - von der Assen, Albert

AU - Wölber, Linn

AU - Witzel, Isabell

AU - Schmalfeldt, Barbara

AU - Geist, Stefan

AU - Paluchoswski, Peter

AU - Wilke, Christian

AU - Heilenkötter, Uwe

AU - Terracciano, Luigi

AU - Müller, Volkmar

AU - Wilczak, Waldemar

AU - Burandt, Eike Christian

PY - 2019/9/18

Y1 - 2019/9/18

N2 - Dysregulation of lipid metabolism is common in cancer. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been implicated with various cancer types. Here we analyzed by immunohistochemistry its expression in 2,197 breast cancers. LPCAT1 staining was found in 97.8% of 1,774 interpretable tumors, including 48.1% with weak, 28.7% with moderate, and 14.4% with strong expression. The frequency of LPCAT1 positivity depended on the histological tumor type. Moderate or strong LPCAT1 positivity was more common in cancers of no special type (NST) (46.2%) than in lobular carcinomas (25.9%; p<0.0001). Strong LPCAT1 was associated with BRE grade, tumor cell proliferation and overall survival in all cancers and in the subgroup of NST cancers (p<0.0001, each). In the subset of NST cancers the prognostic effect of LPCAT1 expression was independent of pT, and BRE grade (p<0.0001 each). A comparison with molecular features showed that LPCAT1 was strongly associated with estrogen receptor negativity (p<0.0001), progesterone receptor negativity (p<0,0001), amplification of HER2 (p<0.0001) and MYC (p=0.0066), as well as deletions of PTEN (p<0.0001) and CDKNA2 (p=0.0151). It is concluded that LPCAT1 overexpression is linked to adverse tumor features and poor prognosis in breast cancer. These data also highlight the important role of lipid metabolism in breast cancer biology.

AB - Dysregulation of lipid metabolism is common in cancer. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) has been implicated with various cancer types. Here we analyzed by immunohistochemistry its expression in 2,197 breast cancers. LPCAT1 staining was found in 97.8% of 1,774 interpretable tumors, including 48.1% with weak, 28.7% with moderate, and 14.4% with strong expression. The frequency of LPCAT1 positivity depended on the histological tumor type. Moderate or strong LPCAT1 positivity was more common in cancers of no special type (NST) (46.2%) than in lobular carcinomas (25.9%; p<0.0001). Strong LPCAT1 was associated with BRE grade, tumor cell proliferation and overall survival in all cancers and in the subgroup of NST cancers (p<0.0001, each). In the subset of NST cancers the prognostic effect of LPCAT1 expression was independent of pT, and BRE grade (p<0.0001 each). A comparison with molecular features showed that LPCAT1 was strongly associated with estrogen receptor negativity (p<0.0001), progesterone receptor negativity (p<0,0001), amplification of HER2 (p<0.0001) and MYC (p=0.0066), as well as deletions of PTEN (p<0.0001) and CDKNA2 (p=0.0151). It is concluded that LPCAT1 overexpression is linked to adverse tumor features and poor prognosis in breast cancer. These data also highlight the important role of lipid metabolism in breast cancer biology.

U2 - 10.18632/aging.102287

DO - 10.18632/aging.102287

M3 - SCORING: Journal article

C2 - 31533087

VL - 11

SP - 7796

EP - 7804

JO - AGING-US

JF - AGING-US

SN - 1945-4589

IS - 18

ER -